Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bosakitug - Biosion

Next Previous
X
Search
Drug Profile

Bosakitug - Biosion

Alternative Names: Anti-TSLP mAb; BSI-045B; TQC-2731

Latest Information Update: 28 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biosion
  • Developer Biosion; Chia Tai Tianqing Pharmaceutical Group
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Thymic stromal lymphopoietin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Asthma; Atopic dermatitis; Rhinosinusitis
  • Phase I Chronic obstructive pulmonary disease; Hypersensitivity

Most Recent Events

  • 28 Jul 2024 No recent reports of development identified for phase-I development in Asthma in China (IV, Injection)
  • 04 Jul 2024 Chia Tai Tianqing Pharmaceutical Group initiates enrolment in a phase II trial for Rhinosinusitis in China (SC)(NCT06451640)
  • 11 Jun 2024 Chia Tai Tianqing Pharmaceutical Group plans a phase II trial for Rhinosinusitis in China (Injection) in June 2024 (NCT06451640)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top